[Retracted] NOD1 and NOD2 Are Potential Therapeutic Targets for Cancer Immunotherapy

Figure 3

NOD1 and NOD2 activation in response to PGN. Initially, NOD1 and NOD2 were suppressed by LRRs binding to NOD. Once PNG was recognized and bound to LRRs, NOD1 and NOD2 are activated by binding RIP2 and TAK1, which further activated the MAPK, NF-κB, and type I interferon signaling pathways.